Use of Immunotherapy for HCCOncLiveTranscript: Catherine T. Frenette, MD: How do you choose which patients would be appropriate for immunotherapy? Darren S. Sigal, MD: So, right now, in the second-line setting, we have 2 approved options. One is regora… Continue reading
Medical News BulletinIs gene therapy ready to treat optic nerve disease?Medical News BulletinGene therapy is a promising therapeutic tool for treating genetic defects. In a recent review, researchers in the US comb over the data to determine if gene th… Continue reading
BioPharma-Reporter.comNovartis invests $55m in US gene therapy site, prepares BLABioPharma-Reporter.comThe clinical-stage gene therapy firm will invest $55m into the site – located in Research Triangle Park, North Carolina, US – and add 200 jobs in eng… Continue reading
BioPharma-Reporter.comNovartis invests $55m in US gene therapy site, prepares BLABioPharma-Reporter.comThe clinical-stage gene therapy firm will invest $55m into the site – located in Research Triangle Park, North Carolina, US – and add 200 jobs in eng… Continue reading
FiercePharmaAbeona Therapeutics opens gene therapy manufacturing, immediately starts on expansionFiercePharmaAbeona, with a market cap of $670 million, is working on a series of trials, including a gene therapy for the lysosomal storage disease Sanfili… Continue reading
MIT Technology Review |
FDA Puts Clinical Trial for CRISPR Therapy on Hold
Labiotech.eu (blog) The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease. CRISPR Therapeutics, based in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to … FDA halts one of the first human CRISPR studies before it beginsMIT Technology Review The FDA Puts the Brakes on a Major CRISPR Trial in HumansFuturism Is Crispr Therapeutics Stock a Bad News Buy?Motley Fool Bloomberg –Xconomy –FierceBiotech –CRISPR | News Release – CRISPR Therapeutics all 104 news articles » |
MIT Technology Review |
FDA Puts Clinical Trial for CRISPR Therapy on Hold
Labiotech.eu (blog) The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease. CRISPR Therapeutics, based in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to … FDA halts one of the first human CRISPR studies before it beginsMIT Technology Review The FDA Puts the Brakes on a Major CRISPR Trial in HumansFuturism Is Crispr Therapeutics Stock a Bad News Buy?Motley Fool Bloomberg –Xconomy –FierceBiotech –CRISPR | News Release – CRISPR Therapeutics all 104 news articles » |